Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that ... Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.1802 | -10.8554216867 | 1.66 | 1.79 | 1.415 | 8587661 | 1.6197471 | CS |
| 4 | 0.6898 | 87.3164556962 | 0.79 | 1.88 | 0.67521 | 17453375 | 1.33345001 | CS |
| 12 | 1.2298 | 491.92 | 0.25 | 1.88 | 0.2066 | 19521660 | 0.73904212 | CS |
| 26 | 0.839 | 130.930087391 | 0.6408 | 1.88 | 0.1611 | 11812610 | 0.67998955 | CS |
| 52 | -0.1202 | -7.5125 | 1.6 | 3.39 | 0.1611 | 7691774 | 0.89570859 | CS |
| 156 | -0.2702 | -15.44 | 1.75 | 12.8499 | 0.1611 | 4126038 | 0.98292682 | CS |
| 260 | -1.0202 | -40.808 | 2.5 | 12.8499 | 0.1611 | 2952572 | 1.10752233 | CS |
techno53
3日前
Whalatane
5日前
Whalatane
5日前
techno53
5日前
WizardSanctuary18
5日前
shurtha2000
6日前
Whalatane
1週前
techno53
1週前
techno53
1週前
techno53
1週前
techno53
1週前
techno53
2週前
techno53
2週前
WizardSanctuary18
2週前
WizardSanctuary18
2週前
WizardSanctuary18
2週前
WizardSanctuary18
2週前
techno53
2週前
Golden Bear 86
2週前
techno53
2週前
Shadonnie
3週前
techno53
3週前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。